Pipex Pharmaceuticals (PPXP) Completes Corporate Name Change to Adeona Pharmaceuticals (AEN) and Receives New Ticker Symbol
10/16/2008 9:20:25 AM
More...
|
Pipex Pharmaceuticals (PPXP)' Oral Flupirtine Receives IRB Approval to Initiate Phase II Clinical Trial for Fibromyalgia
10/7/2008 9:02:23 AM
More...
|
Pipex Pharmaceuticals (PPXP) To Present At The Maxim Group Growth Conference On October 7th
10/6/2008 11:26:30 AM
More...
|
Pipex Pharmaceuticals (PPXP)' Oral TRIMESTA Phase IIa Clinical and Preclinical Findings Presented at World Congress on Treatment and Research in Multiple Sclerosis Meeting
9/19/2008 9:25:48 AM
More...
|
Pipex Pharmaceuticals (PPXP) to Present at the RedChip Small Cap Investor Conference in New York City
8/19/2008 10:01:03 AM
More...
|
Pipex Pharmaceuticals (PPXP) Acquires Late-Stage Oral Phase II Candidate for Rheumatoid Arthritis
8/19/2008 8:24:18 AM
More...
|
Pipex Pharmaceuticals (PPXP) to Present at the Noble Financial Equity Conference
8/12/2008 8:45:49 AM
More...
|
Pipex Pharmaceuticals (PPXP) to Host Conference Call at 10:15am ET Wednesday July 9th to Discuss Phase II Clinical Trial Results in Dry Age-Related Macular Degeneration (AMD) With Oral Z-Monocys
7/9/2008 8:35:41 AM
More...
|
Pipex Pharmaceuticals (PPXP) Announces Results of Eighty Patient, Six Month, Prospective, Randomized, Double-Blind Clinical Trial of Oral Zinthionein for Dry Age-Related Macular Degeneration (AMD); Study Meets All Global Central Retinal Function Measurements
7/9/2008 8:28:13 AM
More...
|
Pipex Pharmaceuticals (PPXP) Appoints CEO
7/8/2008 6:37:27 AM
More...
|
|